Business Segment Information Business Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Segment Reporting Information [Line Items]
Revenues		$ 808,924	$ 774,261	$ 2,233,988	$ 2,207,904
Segment operating income		147,030	142,387	402,294	379,208
Restructuring Charges	[1]	20	385	110	3,328
Amortization of acquired intangible assets	[2]	23,194	17,508	62,649	53,407
Business Combination, Acquisition Related Costs	[3]	11,563	1,721	13,984	5,585
loss (gain) on fair value contingent consideration adjustments		(500)	0	(500)	0
Impact of TCJA	[4]	296	487	850	3,274
Net loss on divestiture of businesses	[2]	0	76	5	2,553
Amortization of inventory and property step-up to fair value	[2]	1,784	602	3,101	1,783
COVID-19 incremental costs	[5]	7,251	0	20,460	0
Assets		6,580,780		6,580,780		$ 5,425,582
Life Sciences
Segment Reporting Information [Line Items]
Revenues		110,800	108,773	343,370	304,208
Segment operating income		41,541	37,731	136,435	103,085
Applied Sterilization Technologies
Segment Reporting Information [Line Items]
Revenues		176,462	156,266	498,371	463,459
Segment operating income		81,626	65,468	222,416	198,889
Assets		2,985,027		2,985,027		2,720,205
Segment operating income
Segment Reporting Information [Line Items]
Revenues		808,924	774,261	2,233,988	2,207,904
Segment operating income		190,638	163,166	502,953	449,138
Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues		521,662	509,222	1,392,247	1,440,237
Segment operating income		115,412	105,227	302,565	298,777
Healthcare and Life Sciences [Member]
Segment Reporting Information [Line Items]
Assets		3,595,753		3,595,753		$ 2,705,377
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Segment operating income		(47,941)	(45,260)	(158,463)	(151,613)
Other foreign locations [Member]
Segment Reporting Information [Line Items]
Revenues		216,211	195,633	568,655	549,744
UNITED STATES
Segment Reporting Information [Line Items]
Revenues		572,397	562,502	1,613,554	1,611,755
UNITED KINGDOM
Segment Reporting Information [Line Items]
Revenues		20,316	16,126	51,779	46,405
Consumable revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		49,627	46,370	164,262	132,939
Consumable revenues [Member] | Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues		148,839	130,255	355,390	362,370
Sales Revenue, Services, Net [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		32,180	30,641	90,444	86,276
Sales Revenue, Services, Net [Member] | Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues		224,968	223,559	629,247	648,973
Capital equipment revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		28,993	31,762	88,664	84,993
Capital equipment revenues [Member] | Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues		$ 147,855	$ 155,408	$ 407,610	$ 428,894

[1] For more information regarding our restructuring efforts refer to Note 17 titled, "Restructuring"

[2] For more information regarding our recent acquisitions and divestitures refer to Note 2 titled" Business Acquisitions and Divestitures" and our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.

[3] Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

[4] Costs incurred in connection with the Redomiciliation and tax restructuring.

[5] COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.